section name header

Pronunciation ⬇

a-to-MOX-e-teen

Classifications ⬆ ⬇

Therapeutic Classification: agents for attention deficit disorder

Pharmacologic Classification: selective norepinephrine reuptake inhibitors

Indications ⬆ ⬇

REMS

Action ⬆ ⬇

  • Selectively inhibits the presynaptic transporter of norepinephrine.
Therapeutic effects:
  • Increased attention span.

Pharmacokinetics ⬆ ⬇

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 98%.

Metabolism/Excretion: Mostly metabolized by the liver (CYP2D6 enzyme pathway); the CYP2D6 enzyme system exhibits genetic polymorphism (∼7% of population may be poor metabolizers and may have significantly ↑ atomoxetine concentrations and an ↑ risk of adverse effects).

Half-Life: 5 hr.

Time/Action Profile ⬆ ⬇

ROUTEONSETPEAKDURATION
POunknown1–2 hr12–24 hr



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypertension, orthostatic hypotension, QT interval prolongation, syncope, tachycardia

Derm: ↑sweating, rash, urticaria

GI: nausea, vomiting, dyspepsia, HEPATOTOXICITY,

Adults

constipation, dry mouth

GU:

Adults

dysmenorrhea, ejaculatory problems, erectile dysfunction, libido changes, priapism, urinary hesitation, urinary retention

Metab: ↓appetite, weight/growth loss

MS: RHABDOMYOLYSIS

Neuro: dizziness, fatigue, insomnia, mood swings, aggression, behavioral disturbances, delusions, hallucinations, hostility, mania, paresthesia, SUICIDAL THOUGHTS, thought disorder

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Hepatic Impairment

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Strattera

Code ⬆

NDC Code